Research Study for NASH

UVA Tracking #
HSR210422
Principal Investigator
Stephen H Caldwell
Contact
Cheree Denby Taylor
Contact Email
Contact Phone
434.924.2169
Official Trial Title
A randomized, double-blind, placebo-controlled, multicenter, Phase 3 study evaluating long-term efficacy and safety of Lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of live
Study Description

The Gastroenterology & Hepatology seeks adults over age 18 with NASH for a research study. The purpose of the study is see if an investigational drug (lanifibranor) is effective at reducing fibrosis.

Study involves taking an experimental medicine/placebo by mouth daily, blood draws, liver biopsy, fibroscan, EKGs, optional DEXA scans, and daily weight measurements. Study involves at least 22 visits to UVA over approximately 7 years.

Study-related exams, tests and experimental medication provided free of charge.

Compensation

$104/visit